KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$249.2 million.

  • Emergent BioSolutions' Enterprise Value fell 5933.5% to -$249.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$249.2 million, marking a year-over-year decrease of 5933.5%. This contributed to the annual value of -$105.6 million for FY2024, which is 546.11% up from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Enterprise Value is -$249.2 million, which was down 5933.5% from -$271.0 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Enterprise Value peaked at -$71.0 million during Q2 2024, and registered a low of -$642.6 million during Q4 2022.
  • Moreover, its 5-year median value for Enterprise Value was -$249.2 million (2025), whereas its average is -$287.2 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first surged by 8261.75% in 2023, then tumbled by 28169.01% in 2025.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Enterprise Value stood at -$576.3 million in 2021, then decreased by 11.5% to -$642.6 million in 2022, then surged by 82.62% to -$111.7 million in 2023, then increased by 5.46% to -$105.6 million in 2024, then crashed by 135.98% to -$249.2 million in 2025.
  • Its last three reported values are -$249.2 million in Q3 2025, -$271.0 million for Q2 2025, and -$152.8 million during Q1 2025.